Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15468170 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL126194 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL21547377 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL12344760 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL16645332 | 1.00 | HSD17B10 (0.52) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| Bromide SCHEMBL2542868 | 0.98 | HSD17B10 (0.50) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1375642 | 0.98 | HSD17B10 (0.50) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL16645317 | 0.93 | HSD17B10 (0.47) | HSD17B10MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL29299530 | 0.91 | HSD17B10 (0.45) | HSD17B10MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL20686921 | 0.91 | HSD17B10 (0.45) | HSD17B10MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023250-A1 | DUAL MODE RADIOTRACER AND -THERAPEUTICS | Technische Universität München (DE) | 2022-07-06 | — | — | EP | disclosed |
| WO-2022078566-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-04-21 | — | — | WO | disclosed |
| US-20170145076-A1 | Peptide-Mediated Non-Covalent Delivery of Active Agents Across the Blood-Brain Barrier | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-05-25 | — | — | US | disclosed |
| US-9597408-B2 | Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170007669-A1 | PEPTIDE-MEDIATED DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2017-01-12 | — | — | US | disclosed |
| US-20140328866-A1 | Peptide-Mediated Non-Covalent Delivery of Active Agents Across the Blood-Brain Barrier | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140314663-A1 | PEPTIDE-MEDIATED DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2014-10-23 | — | — | US | disclosed |
| US-8394356-B2 | Diagnostic imaging contrast agents with extended blood retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120107249-A1 | Diagnostic Imaging Contrast Agents with Extended Blood Retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120107243-A1 | PEPTIDE-MEDIATED NON-COVALENT DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2012-05-03 | — | — | US | disclosed |
| US-7635464-B2 | Selective targeting of apoptotic cells | NEW SOUTH INNOVATIONS PTY LIMITED (AU) | 2009-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140328866-A1 | Peptide-Mediated Non-Covalent Delivery of Active Agents Across the Blood-Brain Barrier | FABP7, NPPA, LNPEP | HSD17B10 4335/4885MEN1 740/4885KMT2A 4324/4885 |
| US-20140314663-A1 | PEPTIDE-MEDIATED DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER | NPPA, FABP7, TAP2 | HSD17B10 4736/4885MEN1 146/4885KMT2A 2482/4885 |
| US-20170007669-A1 | PEPTIDE-MEDIATED DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER | AQP4, TAP1, LNPEP | HSD17B10 4795/4885MEN1 561/4885KMT2A 3814/4885 |
| US-20120107243-A1 | PEPTIDE-MEDIATED NON-COVALENT DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER | FABP7, NPPA, LNPEP | HSD17B10 4335/4885MEN1 740/4885KMT2A 4324/4885 |
| US-20120107249-A1 | Diagnostic Imaging Contrast Agents with Extended Blood Retention | FABP1, B2M, BHMT | HSD17B10 3389/4885MEN1 577/4885KMT2A 2284/4885 |
| US-20170145076-A1 | Peptide-Mediated Non-Covalent Delivery of Active Agents Across the Blood-Brain Barrier | FABP7, NPPA, LNPEP | HSD17B10 4335/4885MEN1 740/4885KMT2A 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.